Research Peptides: Advanced Growth Stack 2026

Veyvora’s Advanced Growth Stack is a two-pen research bundle pairing CJC-1295 + Ipamorelin 20 with Somatropin 100 recombinant growth hormone, listed as available on the Veyvora UK catalogue as of 30 August 2026 with a bundle-and-save discount applied; the stack is supplied strictly for laboratory research use only and is not a medicine or consumer product [1].

The Advanced Growth Stack for research pairs nightly secretagogue pulses from the CJC-1295 + Ipamorelin 20 pen with exogenous recombinant growth hormone from the Somatropin 100 pen, forming a two-component growth-axis research protocol available from Veyvora’s UK catalogue as of 30 August 2026; the bundle carries a stated percentage saving over individual pen prices, though the exact GBP figure is not surfaced in the current page capture and requires operator confirmation [1].

Research Peptides: Advanced Growth Stack 2026: Exact Bundle Identity

Veyvora’s Advanced Growth Stack is a two-pen research bundle comprising a CJC-1295 + Ipamorelin 20 dual growth-hormone secretagogue pen and a Somatropin 100 recombinant growth-hormone pen, listed as available on the Veyvora UK catalogue as of 30 August 2026 and supplied strictly for laboratory research use only [1].

Veyvora also lists a distinct Muscle Growth stack pairing Tesamorelin 20 with Somatropin 100, so the site applies growth-axis naming across multiple bundle formats rather than a single universal SKU [1]. The Advanced Growth Stack is therefore best identified by its bundle name together with its two confirmed pen components: CJC-1295 + Ipamorelin 20 and Somatropin 100.

No additional components beyond those two pens are visible in the current live page content [1]. Before placing an order, researchers should verify your batch against its COA to confirm the delivered pen matches the listed specification, and consult what HPLC purity does and does not prove to interpret the purity field accurately.

Included components

The Advanced Growth Stack contains two separate research pens: CJC-1295 + Ipamorelin 20, a dual growth-hormone secretagogue pen, and Somatropin 100, a recombinant growth-hormone pen. Both are supplied by Veyvora for laboratory research use only, as listed in the Veyvora UK growth catalogue on 30 August 2026 [1].

The “20” and “100” designations follow Veyvora’s catalogue naming convention; exact unit values (IU, mg or mcg per pen) are not exposed in the current live page capture and require operator confirmation before purchase [1]. No additional ingredients beyond these two pens are visible in the current live content [1].

The two pens pair a secretagogue signal with exogenous recombinant GH in separate formats, which is relevant to laboratory workflows requiring independent handling of each compound. For storage requirements that apply once the pens arrive, consult the storage and stability guidance for research peptides. Researchers wanting the mechanistic background on the secretagogue component can refer to the CJC-1295 + Ipamorelin research overview, which covers the two-mechanism secretagogue pen included in this stack.

Bundle-level evidence boundary

The Advanced Growth Stack’s product page describes a research theme and lists two component pens; it does not present clinical outcome data for the combination of CJC-1295 + Ipamorelin 20 and Somatropin 100 as a paired protocol [1]. Evidence that exists for either compound individually, in published literature, does not establish a combined effect for this specific bundle, and no such bundle-level evidence is visible in the current live content [1].

MHRA guidance, last updated 2 July 2026, states that a product can fall within the definition of a medicinal product if it is presented as modifying a physiological function through pharmacological, immunological or metabolic action, regardless of how it is labelled [2]. Regulatory definitions vary by jurisdiction; consult local guidelines for clarity on how this applies to any specific research context [2]. That boundary means claims about efficacy, body composition, recovery or growth outcomes for the Advanced Growth Stack as a bundle are not supported by the product page alone and would require separate primary research with appropriate regulatory framing [1][2].

The two pens are supplied as a paired growth-axis format; each also carries its own batch-specific evidence and COA. To compare other formats in the same research category, the Growth & Recovery research pens catalogue lists the wider compound range available from Veyvora as of 30 August 2026 [1]. Once a batch arrives, verify your batch against its COA to confirm the certificate of analysis matches the delivered pen before any laboratory use.

Batch documents and handling

Veyvora states that every pen in its growth catalogue is independently assayed and supplied with a batch-specific certificate of analysis, with each COA linked to the batch number of the delivered pen [1]. That documentation model applies to the pen line as a whole, including both CJC-1295 + Ipamorelin 20 and Somatropin 100 as individual reagents within the Advanced Growth Stack [1].

The COA covers HPLC purity, mass spectrometry confirmation and endotoxin testing, according to Veyvora’s testing documentation [1]. Understanding what HPLC purity does and does not prove is relevant here: a purity figure confirms compound identity and the absence of detectable impurities at the stated threshold, but does not establish biological activity or suitability for any specific assay format.

Specific cold-chain temperatures, transit windows and stability data for the Advanced Growth Stack are not exposed in the current live catalogue text, so those values require operator confirmation before publication [1]. For post-arrival handling, storage and stability guidance for research peptides covers the conditions under which peptide pens should be maintained once received. The MHRA notes that a batch document alone does not determine a product’s regulatory status; classification depends on claims, intended purpose and presentation as of 2 July 2026 [2].

Commercial terms

Veyvora lists the Advanced Growth Stack as a bundle-and-save offer, with a 12% saving displayed on the category page as of 30 August 2026 [1]. No numeric GBP price for the bundle is exposed in the current live catalogue text, so the exact retail figure requires operator confirmation before publication [1]. Similarly, shipping thresholds, delivery windows, minimum order quantities and real-time stock status for this specific stack are not surfaced in the captured page content and must be treated as unverified [1].

Buyers can browse the full range of formats and compounds at Growth & Recovery research pens to compare individual pen pricing against the bundle saving. Veyvora states that prices are displayed in the selected currency, which for UK buyers means GBP, but no structured price data for the Advanced Growth Stack is currently available to confirm a specific figure [1]. Confirm current pricing, availability and any applicable shipping terms directly on the merchant’s bundle page before placing an order.

Research-use-only limitations

Veyvora supplies the Advanced Growth Stack strictly for in-vitro and laboratory research; the pens are not medicines and are not intended for human or veterinary consumption [1]. That designation is a use restriction, not a regulatory clearance. Under MHRA guidance updated 2 July 2026, a product becomes a medicinal product if it is presented as preventing or treating disease, or if it is used to restore, correct or modify a physiological function by pharmacological, immunological or metabolic action [2]. Regulatory definitions vary across jurisdictions, so researchers and prospective distributors should consult local guidelines for clarity on how these boundaries apply to their specific procurement context.

A batch-specific certificate of analysis confirms identity and purity at the point of manufacture; it does not confer lawful status for any use beyond the stated research purpose. To interpret what a purity figure actually establishes, see what HPLC purity does and does not prove before drawing analytical conclusions from the COA.

No dosing guidance, treatment framing, body-composition claims or outcome promises appear on the Advanced Growth Stack product page, and none are supported by the bundle-level evidence available as of 30 August 2026 [1][2]. To confirm that the pen delivered to your laboratory matches its documented batch, verify your batch against its COA as the concrete next step before beginning any in-vitro work.

Sources

[1] Growth & Recovery Research Pens | Veyvora, veyvora.com, https://veyvora.com/categories/growth [2] Borderline products: how to tell if your product is a medicine - GOV.UK, gov.uk, 2026, https://www.gov.uk/guidance/borderline-products-how-to-tell-if-your-product-is-a-medicine